REYON Pharmaceutical Statistics

Total Valuation

REYON Pharmaceutical has a market cap or net worth of KRW 234.03 billion. The enterprise value is 380.09 billion.

Market Cap	234.03B
Enterprise Value	380.09B

Important Dates

The next estimated earnings date is Wednesday, February 12, 2025.

Earnings Date	Feb 12, 2025
Ex-Dividend Date	Dec 27, 2024

Share Statistics

REYON Pharmaceutical has 18.34 million shares outstanding. The number of shares has decreased by -1.91% in one year.

Current Share Class	n/a
Shares Outstanding	18.34M
Shares Change (YoY)	-1.91%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	53.55%
Owned by Institutions (%)	3.83%
Float	8.02M

Valuation Ratios

The trailing PE ratio is 380.05.

PE Ratio	380.05
Forward PE	n/a
PS Ratio	1.56
PB Ratio	0.95
P/TBV Ratio	0.95
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 56.81, with an EV/FCF ratio of -19.38.

EV / Earnings	617.23
EV / Sales	2.54
EV / EBITDA	56.81
EV / EBIT	147.88
EV / FCF	-19.38

Financial Position

The company has a current ratio of 0.63, with a Debt / Equity ratio of 0.62.

Current Ratio	0.63
Quick Ratio	0.34
Debt / Equity	0.62
Debt / EBITDA	18.67
Debt / FCF	-7.77
Interest Coverage	21.94

Financial Efficiency

Return on equity (ROE) is 0.25% and return on invested capital (ROIC) is 0.58%.

Return on Equity (ROE)	0.25%
Return on Assets (ROA)	0.51%
Return on Capital (ROIC)	0.58%
Revenue Per Employee	334.47M
Profits Per Employee	1.37M
Employee Count	448
Asset Turnover	0.30
Inventory Turnover	2.23

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -15.49% in the last 52 weeks. The beta is 1.00, so REYON Pharmaceutical's price volatility has been similar to the market average.

Beta (5Y)	1.00
52-Week Price Change	-15.49%
50-Day Moving Average	14,541.00
200-Day Moving Average	14,241.70
Relative Strength Index (RSI)	40.57
Average Volume (20 Days)	32,744

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, REYON Pharmaceutical had revenue of KRW 149.84 billion and earned 615.80 million in profits. Earnings per share was 33.20.

Revenue	149.84B
Gross Profit	73.13B
Operating Income	4.05B
Pretax Income	1.34B
Net Income	615.80M
EBITDA	8.17B
EBIT	4.05B
Earnings Per Share (EPS)	33.20

Full Income Statement

Balance Sheet

The company has 6.42 billion in cash and 152.48 billion in debt, giving a net cash position of -146.05 billion or -7,963.29 per share.

Cash & Cash Equivalents	6.42B
Total Debt	152.48B
Net Cash	-146.05B
Net Cash Per Share	-7,963.29
Equity (Book Value)	247.40B
Book Value Per Share	13,488.91
Working Capital	-48.77B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 3.73 billion and capital expenditures -23.34 billion, giving a free cash flow of -19.61 billion.

Operating Cash Flow	3.73B
Capital Expenditures	-23.34B
Free Cash Flow	-19.61B
FCF Per Share	-1,069.34

Full Cash Flow Statement

Margins

Gross margin is 48.81%, with operating and profit margins of 2.70% and 0.41%.

Gross Margin	48.81%
Operating Margin	2.70%
Pretax Margin	0.89%
Profit Margin	0.41%
EBITDA Margin	5.45%
EBIT Margin	2.70%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 150.00, which amounts to a dividend yield of 1.18%.

Dividend Per Share	150.00
Dividend Yield	1.18%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	446.76%
Buyback Yield	1.91%
Shareholder Yield	3.08%
Earnings Yield	0.26%
FCF Yield	-8.38%

Dividend Details

Stock Splits

The last stock split was on December 29, 2020. It was a forward split with a ratio of 1.02.

Last Split Date	Dec 29, 2020
Split Type	Forward
Split Ratio	1.02

Scores

REYON Pharmaceutical has an Altman Z-Score of 1.44. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.44
Piotroski F-Score	n/a